An ongoing dialogue on HIV/AIDS, infectious diseases,
September 18th, 2009
Integrase Inhibitors: In Search of an Abbreviation
The alphabet soup that characterizes HIV therapeutics has always been one of its quirky challenges — for example, who could possibly know that 3TC, CBV, TZV, EPZ, and LAM all refer to drugs that are (or contain) lamivudine?
This drives our ID fellows nuts, and is certainly a strong deterrent to non-HIV specialists to learning the field.
(Maybe that’s why they pay us the big bucks… oh wait.)
And while we’ve grown comfortable with the abbreviations for the 3 oldest drug classes — NRTI, NNRTI, and PI — what are we to do with integrase inhibitors? Some candidates:
- “II” — sounds funny when you say it (“eye-eye”), and could be confused with “eleven” depending on the font
- “INSTI” — for “integrase strand transfer inhibitor”; I’ve already seen this one around a lot, but have also seen it written “InSTI” (lower-case n), which is hard to type
- “INI” — for “INtegrase Inhibitor”; same upper vs lower-case issue as “INSTI”, and saying “INI” always has an anatomic (especially umbilical) connotation to it
Still not sure where we’ll end up with this one, but I suspect “INSTI” will rule the day.
Comments are closed.
Paul E. Sax, MD
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- Endless Recertification in Medicine — Some Thoughts About the Tests We Take
- Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy — Time to Modify Treatment Guidelines?
- My Vote for the Weirdest Antibiotic on the Planet
- Learning the Names of HIV Drugs Is Horribly Difficult — Here’s Why
- Really Rapid Review — Brisbane IAS 2023
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
- Missed Chances for Screening in Persons Newly Diagnosed with HIV: New York City, 2018–2022
- Arboviral Disease Surveillance in the U.S.
- Observations from ID and Beyond: Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy — Time to Change Treatment Guidelines?
- Risk for C. difficile Infection Varies Widely with Choice of Antibiotic
- Mpox in Persons with Previous Infection or Vaccination
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster